UBS Group
KYMR icon

UBS Group’s Kymera Therapeutics KYMR Stock Holding History

UBS Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$116M Buy
1,034,482
+26,705
+3% +$3.06M 0.02% 999
2026
Q2 		$116M Sell
1,007,777
-16,075
-2% -$1.38M 0.01% 1024
2026
Q1 		$85.3M Buy
1,023,852
+286,820
+39% +$22.7M 0.01% 1174
2025
Q4 		$57.3M Buy
737,032
+88,314
+14% +$5.96M 0.01% 1472
2025
Q3 		$36.7M Buy
648,718
+90,984
+16% +$4.1M 0.01% 1941
2025
Q2 		$24.3M Sell
557,734
-35,872
-6% -$1.24M ﹤0.01% 2170
2025
Q1 		$16.2M Buy
593,606
+123,764
+26% +$4.51M ﹤0.01% 2551
2024
Q4 		$18.9M Buy
469,842
+252,223
+116% +$11.4M ﹤0.01% 2384
2024
Q3 		$10.3M Buy
217,619
+7,318
+3% +$323K ﹤0.01% 2338
2024
Q2 		$6.28M Sell
210,301
-86,379
-29% -$2.99M ﹤0.01% 2634
2024
Q1 		$11.9M Sell
296,680
-3,783
-1% -$135K ﹤0.01% 2124
2023
Q4 		$7.65M Buy
300,463
+137,704
+85% +$2.46M ﹤0.01% 2335
2023
Q3 		$2.26M Sell
162,759
-77,957
-32% -$1.57M ﹤0.01% 3328
2023
Q2 		$5.53M Buy
240,716
+55,421
+30% +$1.59M ﹤0.01% 2480
2023
Q1 		$5.49M Sell
185,295
-17,466
-9% -$563K ﹤0.01% 2425
2022
Q4 		$5.06M Buy
202,761
+153,076
+308% +$4.08M ﹤0.01% 2496
2022
Q3 		$1.08M Sell
49,685
-61,784
-55% -$1.63M ﹤0.01% 3688
2022
Q2 		$2.19M Sell
111,469
-24,621
-18% -$575K ﹤0.01% 3075
2022
Q1 		$5.76M Buy
136,090
+66,974
+97% +$2.83M ﹤0.01% 2404
2021
Q4 		$4.39M Buy
69,116
+55,873
+422% +$3.25M ﹤0.01% 2962
2021
Q3 		$778K Sell
13,243
-13,297
-50% -$771K ﹤0.01% 4397
2021
Q2 		$1.29M Buy
26,540
+1,098
+4% +$47.7K ﹤0.01% 3963
2021
Q1 		$989K Buy
25,442
+21,829
+604% +$1.31M ﹤0.01% 4257
2020
Q4 		$224K Buy
3,613
+3,382
+1,464% +$165K ﹤0.01% 5169
2020
Q3 		$7K Buy
+231
New +$7.05K ﹤0.01% 7122

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

UBS Group's KYMR Position: Q3 2026 in Review

UBS Group increased its Kymera Therapeutics (KYMR) stake by 2.6% in Q3 2026, buying an estimated $3.06M and bringing the position to 1,034,482 shares worth $116M. The position accounts for 0.02% of the portfolio, ranked #999.

UBS Group first reported a position in KYMR in Q3 2020 and has held it in 25 quarters since. 173 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • UBS Group held 1,034,482 shares of Kymera Therapeutics worth $116M as of Q3 2026.
  • UBS Group bought 26,705 Kymera Therapeutics shares in Q3 2026, an estimated $3.06M.
  • Kymera Therapeutics made up 0.02% of UBS Group's portfolio in Q3 2026, its #999 holding.
  • UBS Group first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 25 quarters since.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.